Highly sensitized (HS) patients in need of kidney transplantation (KTx) typically spend a longer time waiting for compatible kidneys, are unlikely to receive an organ offer, and are at increased risk of antibody-mediated rejection (AMR). Desensitization using imlifidase, which is more rapid and removes total body immunoglobulin G (IgG) to a greater extent than other methods, enables transplantation to occur between HLA-incompatible (HLAi) donor–recipient pairs and allows patients to have greater access to KTx. However, when the project was launched there was limited data and clinical experience with desensitization in general and with imlifidase specifically. Hence, this Delphi methodology was used to reach a consensus from a multi-disciplinary team (MDT) of experts from 15 countries on the management of HS patients undergoing imlifidase HLAi from a deceased donor (DD) KTx. This Delphi consensus provides clinical practice guidance on the use of imlifidase in the end-to-end management of HS patients undergoing an HLAi DD KTx and supports centers in the development of guidelines for the utilization and integration of imlifidase into clinical practice.
Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus / Furian, L.; Heemann, U.; Bengtsson, M.; Bestard, O.; Binet, I.; Bohmig, G. A.; Boletis, J.; Briggs, D.; Claas, F. H. J.; Couzi, L.; Cozzi, E.; Crespo, M.; De Vries, A. P. J.; Diekmann, F.; Durlik, M.; Glotz, D.; Helantera, I.; Jackson, A.; Jordan, S. C.; Kuypers, D.; Lefaucheur, C.; Legendre, C.; Lorant, T.; Maggiore, U.; Mamode, N.; Marinaki, S.; Massart, A.; Muller, T.; Oberbauer, R.; Renders, L.; Roelen, D.; Taupin, J. -L.; Viklicky, O.; Vittoraki, A.; de Weerd, A. E.; Naesens, M.. - In: TRANSPLANT INTERNATIONAL. - ISSN 0934-0874. - 37:(2024). [10.3389/ti.2024.13886]
Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus
Cozzi E.;Maggiore U.;
2024-01-01
Abstract
Highly sensitized (HS) patients in need of kidney transplantation (KTx) typically spend a longer time waiting for compatible kidneys, are unlikely to receive an organ offer, and are at increased risk of antibody-mediated rejection (AMR). Desensitization using imlifidase, which is more rapid and removes total body immunoglobulin G (IgG) to a greater extent than other methods, enables transplantation to occur between HLA-incompatible (HLAi) donor–recipient pairs and allows patients to have greater access to KTx. However, when the project was launched there was limited data and clinical experience with desensitization in general and with imlifidase specifically. Hence, this Delphi methodology was used to reach a consensus from a multi-disciplinary team (MDT) of experts from 15 countries on the management of HS patients undergoing imlifidase HLAi from a deceased donor (DD) KTx. This Delphi consensus provides clinical practice guidance on the use of imlifidase in the end-to-end management of HS patients undergoing an HLAi DD KTx and supports centers in the development of guidelines for the utilization and integration of imlifidase into clinical practice.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
